Search clinical trials for: Allogeneic stem cell transplantation

Total 63295 results

Genentech, Inc.

Completed

Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Acute Graft-versus-host Disease

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host Disease | Precancerous/Nonmalignant Condition
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Leukemia

United States
Guenther Koehne

Suspended

CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome

Myelodysplastic Syndromes | Graft Vs Host Disease | Graft-versus-host-disease

United States
The First Affiliated Hospital of Soochow University

Withdrawn

Clinical Study on the Impact of Covid-19 Vaccine on Allogeneic Hematopoietic Stem Cell Transplantation

Hematologic Diseases

China
National Cancer Institute (NCI)

Active, not recruiting

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia

United States, Canada, Puerto Rico, Australia, New Zealand
Hospices Civils de Lyon
BioMérieux

Completed

Immune Response to Vaccinations in Hematopoietic Stem Cell Transplant Recipients (VaccHemInf)

Vaccination | Hematopoietic Stem Cells

France
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Adult Acute Myeloid Leukemia in Remission | Myelodysplastic Syndrome | Adult Acute Lymphoblastic Leukemia in Remission | Therapy-Related Myelodysplastic Syndrome | Secondary Myelodysplastic...

United States
Massachusetts General Hospital
Millennium Pharmaceuticals, Inc.; Celgene Corporation

Active, not recruiting

Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Roswell Park Cancer Institute
Amgen

Completed

Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant

Osteoporosis | Osteopenia | Allogeneic Hematopoietic Stem Cell Transplantation Recipient

United States
New York Medical College
Washington University School of Medicine; University of California, Los Angeles and other collaborators

Active, not recruiting

Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease (HaploSCD)

Sickle Cell Disease

United States
Versailles Hospital

Active, not recruiting

Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (Allo-SCT) in FLT3-ITD AML Patients (PONALLO)

Leukemia, Myeloid, Acute

France
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia in Remission | Childhood Acute Myeloid Leukemia in Remission | Adult Acute Lymphoblastic Leukemia in Remission | Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent... and other conditions

United States
Ludwig-Maximilians - University of Munich
Amgen

Withdrawn

Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab (DLI-TARGET)

Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia in Remission | B-Cell Acute Lymphoblastic Leukemia | B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell Transplantation

Germany
Sidney Kimmel Comprehensive Cancer Center at Johns...
Gilead Sciences

Terminated

Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | B Cell Chronic Lymphocytic Leukemia | B Cells-Tumors | Large B-Cell Diffuse Lymphoma of Bone (Diagnosis)

United States
Memorial Sloan Kettering Cancer Center

Terminated

Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors

Hodgkin Lymphoma | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Acute Myeloid Leukemia (AML) | Chronic Myeloid Leukemia (CML) | Acute Lymphoid Leukemia (ALL)

United States
CytoDyn, Inc.
Amarex Clinical Research

Terminated

A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation (GVHD)

Graft Vs Host Disease

United States
Massachusetts General Hospital
Agios Pharmaceuticals, Inc.

Completed

IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

IDH1 Mutation Myeloid Neoplasms

United States
Massachusetts General Hospital
Celgene

Completed

IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia

United States
NYU Langone Health

Completed

High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

GVHD

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Incyte Corporation

Active, not recruiting

JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Active, not recruiting

2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies

Hematopoietic and Lymphoid Cell Neoplasm

United States
Sanofi

Withdrawn

A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Allogenic Stem Cell Transplantation
National Heart, Lung, and Blood Institute (NHLBI)

Terminated

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Groupe Francophone des Myelodysplasies
Novartis; Neovii Biotech

Active, not recruiting

Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk

MDS

France
Assistance Publique - Hôpitaux de Paris
GlaxoSmithKline

Terminated

Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation (RESPPEDOBS)

Bronchiolitis Obliterans | Respiratory Disease | Stem Cell Transplant Complications

France
M.D. Anderson Cancer Center

Completed

Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)

Leukemia

United States
Cristina Gasparetto
Agilent Technologies, Inc.

Active, not recruiting

Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT (NK-DCI)

Lymphoid Malignancies | Myeloid Malignancies

United States
European Society for Blood and Marrow Transplantation
Novartis

Completed

Non Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMML

MDS | CMML

Germany, Belgium, Czechia
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer

Myelodysplastic Syndromes | Leukemia
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies

Myelodysplastic Syndromes | Leukemia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan

Lymphoma | Leukemia | Graft Versus Host Disease

United States
Masonic Cancer Center, University of Minnesota

Terminated

Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases

Sickle Cell Disease | Thalassemia | Cerebral Adrenoleukodystrophy | Inherited Metabolic Disorders | High Risk Hematologic Disorders

United States
Medical University of Graz

Completed

HHV-6-specific T-cell Reconstitution Among Children and Adolescents After Allogeneic Stem. (CIRAST HHV-6)

Allogeneic Stem Cell Transplantation
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasms | Atypical Chronic Myeloid Leukemia | Myelodysplastic/Myeloproliferative Overlapping Syndrome

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Active, not recruiting

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD

Lymphoblastic Lymphoma | Childhood Acute Myeloid Leukemia in Remission | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts | Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent... and other conditions

United States
AbbVie

Active, not recruiting

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) (VIALE-T)

Cancer | Acute Myeloid Leukemia (AML)

United States, Australia, Brazil, Canada, China, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Spain, Switzerland, Taiwan, United Kingdom
Merck Sharp & Dohme LLC

Completed

Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030)

Cytomegalovirus (CMV) Infection

United States, Australia, Colombia, France, Germany, Israel, Japan, Mexico, Poland, Spain, Turkey
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Therapy-Related Acute Myeloid Leukemia and other conditions

United States
Oncoimmune, Inc., a subsidiary of Merck & Co.,...
National Cancer Institute (NCI); University of Michigan Rogel Cancer Center; Ohio... and other collaborators

Completed

Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)

Leukemia | Hematopoietic Stem Cell Transplantation | Graft Versus Host Disease

United States
Assistance Publique - Hôpitaux de Paris

Active, not recruiting

To Compare the Efficacy of the Addition of Methotrexate (MTX) to Current Standard Acute Graft-versus-host Disease (GVHD) First-line Treatment With Corticosteroids (MTX-aGVHD)

Stem Cell Transplant Complications | GVHD, Acute | GVH - Graft Versus Host Reaction | Allogeneic Disease

France
St. Jude Children's Research Hospital
Cookies for Kids' Cancer; CURE Childhood Cancer, Inc.

Active, not recruiting

Therapy for Children With Advanced Stage Neuroblastoma

Neuroblastoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma

Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent Aggressive Non-Hodgkin Lymphoma | Recurrent Burkitt Lymphoma | Recurrent Transformed B-Cell Non-Hodgkin Lymphoma

United States
Memorial Sloan Kettering Cancer Center
Swedish Orphan Biovitrum

Active, not recruiting

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

Leukemia | Multiple Myeloma | Non-Hodgkin's Lymphoma | Myelodysplastic Syndrome

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Suspended

Magrolimab in Combination With Azacitidine After Allogeneic HCTin Treating Patients With High-Risk AML or MDS

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Heinrich-Heine University, Duesseldorf
Celgene Corporation; Koordinierungszentrum für Klinische Studien Düsseldorf

Active, not recruiting

IDH2-Post-Allo-Trial for Patients With IDH2-mut Myeloid Neoplasms After Allo-SCT

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Chronic Myelomonocytic Leukemia | IDH2 Gene Mutation | IDH2 R172 | IDH2 R140

Germany
University of Alabama at Birmingham
Miltenyi Biotec, Inc.

Active, not recruiting

Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Related Donors

Hematopoietic Stem Cell Transplantation

United States
Arog Pharmaceuticals, Inc.

Completed

Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients

Acute Myeloid Leukemia

United States
National Cancer Institute (NCI)
Canadian Cancer Trials Group

Active, not recruiting

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

United States, Canada, Israel, Puerto Rico

Search clinical trials for: Allogeneic stem cell transplantation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations